ArticleTranslational oncology2026
Variation in LINE-1 ORF1p expression across histologic and demographic subgroups in non-small cell lung cancers.
Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aberrant activation of Long Interspersed Element-1 (LINE-1) retrotransposons and their encoded proteins has been linked to poor clinical outcomes across multiple malignancies, including non-small cell lung cancers (NSCLC). In this study, we profiled LINE-1 ORF1p expression and its co-localization with immune cells using multiplex immunofluorescence of NSCLC tumors and matched adjacent non-tumor tissues (N = 76). These data were then integrated with clinicopathologic features to assess the potential clinical utility of such measurements. ORF1p expression was significantly elevated in NSCLC compared to non-tumor lung tissues, with higher levels in lung squamous cell carcinoma (LSQCC) than in lung adenocarcinoma (LUAD). Race-stratified analyses showed markedly higher ORF1p levels in African American compared with Caucasian American patients. Although sex-based differences were less consistent, older males exhibited significantly higher ORF1p levels than other subgroups. Age-stratified analyses revealed a positive correlation between ORF1p and increasing age in tumor samples. Co-expression analyses combined with cellular neighborhood enrichment and spatial auto-correlation analyses demonstrated that ORF1p was most strongly associated with CD68⁺ macrophages across both tumor subtypes and representing the most reliably enriched immune cell population in the immediate spatial vicinity of tumor cells with high ORF1p expression. These findings indicate that LINE-1 ORF1p expression in NSCLC is shaped by tumor histology, race, and age, and may be influenced by macrophage-LINE-1 interactions within the tumor microenvironment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.